2020 Year in Review: Amyloidosis

Despite similar rates of major bleed and stroke among African American and Caucasian patients with transthyretin cardiac amyloidosis, African American patients present with fewer cases of atrial fibrillation. Read More ›

In a retrospective analysis at a single center, 15% of patients with light chain amyloidosis cardiomyopathy had significant myocardial uptake on a 99mTc-PYP scan. Read More ›

Tafamidis-treated ATTR-CM patients observed stable functional status and biomarkers, despite a higher proportion of worse NYHA functional class in this real-world population. Read More ›

Both atrial and ventricular arrhythmias are common manifestations of cardiac amyloidosis, frequently necessitating implantation of cardiac electronic devices. Read More ›

Female ATTR V122I patients present predominantly with polyneuropathy phenotype at a younger age, while males present with predominantly cardiovascular or mixed phenotype. Read More ›

Internal quality control and continued education for technologists and readers of PYP scans are important to avoid misdiagnosis. A standardized protocol for evaluation of cardiac amyloidosis could help eliminate variability in testing patterns. Read More ›

Screening for ATTR-CA should be considered in patients with aortic stenosis undergoing transcatheter aortic valve implantation. Read More ›

Based on data from 3 international sites, transcatheter aortic valve replacement should not be withheld in patients with both aortic stenosis and cardiac amyloidosis. Read More ›

Acoramidis (AG10) displays differential TTR binding, kinetic stability, and a higher degree of stabilization compared with tafamidis. Read More ›

Page 1 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: